BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 9053020)

  • 21. Nelfinavir is number 4 -- but should it bat cleanup, or lead off?
    Mascolini M
    J Int Assoc Physicians AIDS Care; 1997 Jun; 3(6):17-21. PubMed ID: 11364427
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy.
    Condra JH; Petropoulos CJ; Ziermann R; Schleif WA; Shivaprakash M; Emini EA
    J Infect Dis; 2000 Sep; 182(3):758-65. PubMed ID: 10950769
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Saquinavir/low-dose ritonavir: its use in HIV infection.
    Johnson M; Peters B
    AIDS Rev; 2003; 5(1):44-51. PubMed ID: 12875107
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Development of HIV protease inhibitors as anti AIDS drugs: molecular design based on substrate transition state].
    Kiso Y
    Tanpakushitsu Kakusan Koso; 1998 May; 43(6):725-33. PubMed ID: 9612066
    [No Abstract]   [Full Text] [Related]  

  • 25. AmFAR extols FDA on rapid approval of two protease inhibitors.
    AIDS Patient Care STDS; 1996 Jun; 10(3):193-4. PubMed ID: 11361645
    [No Abstract]   [Full Text] [Related]  

  • 26. [Diabetes and hyperglycemia in patients under treatment for HIV infection with the protease inhibitors indavir, ritonavir, saquinavir as well as nelfinavir (in development, but not yet released].
    Pharm Unserer Zeit; 1997 Dec; 26(6):317. PubMed ID: 9513575
    [No Abstract]   [Full Text] [Related]  

  • 27. [Protease inhibitors--a class of substances ready to take off].
    Keysser G; Burmester GR
    Dtsch Med Wochenschr; 1997 Jun; 122(25-26):805-7. PubMed ID: 9244667
    [No Abstract]   [Full Text] [Related]  

  • 28. A review of low-dose ritonavir in protease inhibitor combination therapy.
    Cooper CL; van Heeswijk RP; Gallicano K; Cameron DW
    Clin Infect Dis; 2003 Jun; 36(12):1585-92. PubMed ID: 12802760
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Update on antivirals.
    Proj Inf Perspect; 1997 Jul; (22):7-9. PubMed ID: 11364579
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Polymorphism of protease genes in patients infected with HIV-1 and response to therapy including a protease inhibitor].
    Mouroux M; Bossi P; Yvon-Groussin A; Delaugerre C; Valantin MA; Tubiana R; Coutellier A; Bonmarchand M; Bricaire F; Katlama C; Agut H; Huraux JM; Calvez V
    Pathol Biol (Paris); 1999 May; 47(5):549-52. PubMed ID: 10418038
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Saquinavir in the management of HIV infection.
    Moyle G
    Br J Hosp Med; 1997 Jun 4-17; 57(11):560-4. PubMed ID: 9307673
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir.
    Côté HC; Brumme ZL; Harrigan PR
    J Virol; 2001 Jan; 75(2):589-94. PubMed ID: 11134271
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Two more HIV protease inhibitors approved.
    Fox JL
    Nat Biotechnol; 1996 Apr; 14(4):427. PubMed ID: 9669874
    [No Abstract]   [Full Text] [Related]  

  • 34. Update on HIV protease inhibitors.
    Vella S
    AIDS Clin Care; 1995 Oct; 7(10):79-82, 88. PubMed ID: 11362832
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of two randomized trials evaluating the safety and efficacy of indinavir, saquinavir and lopinavir in combination with low-dose ritonavir: the MaxCmin1 and 2 trials.
    Justesen US; Fox Z; Pedersen C; Cahn P; Gerstoft J; Clumeck N; Losso M; Peters B; Obel N; Castagna A; Dragsted UB; Lundgren JD;
    Basic Clin Pharmacol Toxicol; 2007 Nov; 101(5):339-44. PubMed ID: 17910618
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks.
    Kosalaraksa P; Bunupuradah T; Engchanil C; Boonrak P; Intasan J; Lumbiganon P; Burger D; Ruxrungtham K; Schutz M; Ananworanich J;
    Pediatr Infect Dis J; 2008 Jul; 27(7):623-8. PubMed ID: 18520443
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ritonavir-saquinavir dual protease inhibitor compared to ritonavir alone in human immunodeficiency virus-infected patients.
    Michelet C; Ruffault A; Sébille V; Arvieux C; Jaccard P; Raffi F; Bazin C; Chapplain JM; Chauvin JP; Dohin E; Cartier F; Bellissant E
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3393-402. PubMed ID: 11709314
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Different combinations of ritonavir-indinavir.
    TreatmentUpdate; 2001 Sep; 13(5):1-2. PubMed ID: 11768859
    [No Abstract]   [Full Text] [Related]  

  • 39. [Antiretroviral treatment in human immunodeficiency virus infection].
    Blum L; Bachmeyer C
    Ann Dermatol Venereol; 1997; 124(9):641-54. PubMed ID: 9739932
    [No Abstract]   [Full Text] [Related]  

  • 40. Ritonavir-saquinavir rescue therapy in HIV-positive patients failing with indinavir, rotinavir or saquinavir.
    De Wit S; Cassano P; Hermans P; Sommereijns B; Kabeya K; O'Doherty E; Clumeck N
    AIDS; 1999 Sep; 13(13):1794-5. PubMed ID: 10509591
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.